Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually large options trading activity on Wednesday. Stock investors purchased 1,002 put options on the company. This represents an increase of approximately 1,791% compared to the average daily volume of 53 put options.

Institutional Trading of Maravai LifeSciences

A number of large investors have recently made changes to their positions in MRVI. Sprott Inc. acquired a new position in Maravai LifeSciences during the third quarter worth approximately $29,000. Quantessence Capital LLC acquired a new stake in shares of Maravai LifeSciences in the third quarter valued at approximately $31,000. Abel Hall LLC acquired a new stake in shares of Maravai LifeSciences in the third quarter valued at approximately $33,000. CIBC Bancorp USA Inc. purchased a new position in shares of Maravai LifeSciences during the third quarter worth approximately $33,000. Finally, Virtu Financial LLC purchased a new position in shares of Maravai LifeSciences during the fourth quarter worth approximately $34,000. 50.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on MRVI. Wall Street Zen upgraded shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wells Fargo & Company lifted their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.86.

Maravai LifeSciences Price Performance

Shares of NASDAQ:MRVI opened at $3.05 on Thursday. The company’s fifty day moving average price is $3.44 and its 200 day moving average price is $3.29. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $4.11. The company has a debt-to-equity ratio of 0.85, a current ratio of 6.60 and a quick ratio of 5.69. The firm has a market capitalization of $779.92 million, a P/E ratio of -3.39 and a beta of 0.38.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. The company had revenue of $49.87 million during the quarter, compared to the consensus estimate of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 22.79%. As a group, sell-side analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.